Nativ O, Winkler H Z, Farrow G M, Therneau T M, Lieber M M
Department of Urology, Mayo Clinic, Rochester, Minnesota.
Urology. 1994 Feb;43(2):197-202. doi: 10.1016/0090-4295(94)90044-2.
To evaluate the clinical significance of DNA ploidy pattern for patients with nonseminomatous germ cell testicular tumors who did not receive platinum-based chemotherapy.
Flow cytometric nuclear DNA ploidy analysis of paraffin-embedded tissue blocks were used.
All patients underwent radical orchiectomy with or without retroperitoneal lymphadenectomy between 1960 and 1980. Mean follow-up time was eight years. Nineteen percent of the tumors were DNA diploid and 81 percent were DNA aneuploid. Signs of local tumor extension (spermatic cord involvement or vascular invasion) were found in 20 tumors, all were classified as DNA aneuploid (P < 0.04). After primary treatment 9 patients who were clinically cured experienced disease progression; only 1 of them had DNA diploid tumor; the rest were DNA aneuploid (P < 0.05). The ten-year survival rate was higher for patients having DNA diploid tumors compared with those with DNA aneuploid neoplasms (86% versus 53 percent, P < 0.02).
The results of this retrospective study indicate that nuclear DNA content provide important information concerning the natural history and biology of nonseminomatous germ cell testicular tumor.
评估未接受铂类化疗的非精原细胞性睾丸生殖细胞肿瘤患者DNA倍体模式的临床意义。
采用流式细胞术对石蜡包埋组织块进行细胞核DNA倍体分析。
所有患者于1960年至1980年间接受了根治性睾丸切除术,部分患者还接受了腹膜后淋巴结清扫术。平均随访时间为8年。19%的肿瘤为DNA二倍体,81%为DNA非整倍体。20例肿瘤出现局部肿瘤扩展迹象(精索受累或血管侵犯),所有这些肿瘤均被归类为DNA非整倍体(P<0.04)。初始治疗后,9例临床治愈的患者病情进展;其中只有1例患有DNA二倍体肿瘤;其余为DNA非整倍体(P<0.05)。与DNA非整倍体肿瘤患者相比,DNA二倍体肿瘤患者的十年生存率更高(86%对53%,P<0.02)。
这项回顾性研究结果表明,细胞核DNA含量为非精原细胞性睾丸生殖细胞肿瘤的自然病史和生物学特性提供了重要信息。